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Abstract
The objective of this experimentation was to determine if circulating antibody titers to parainfluenza type-3
(PI-3) and infectious bovine rhinotracheitis (IBR) viruses could be enhanced by a combination of vaccines.
The vaccines utilized were a modified live virus vaccine administered by the intranasal route and an
inactivated virus vaccine injected intramuscularly. Virus neutralization tests were conducted on sera obtained
at intervals before and following vaccination. Unfortunately, the calves were apparently exposed naturally to
PI-3 virus, and the responses to that virus were inconclusive. However, antibody responses to IBR virus were
dramatically enhanced by the combination of the two vaccines.
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Summary
The objective of this experimentation was to
determine if circulating antibody titers to
parainfluenza type-3 (PI-3) and infectious bovine
rhinotracheitis (IBR) viruses could be enhanced by a
combination of vaccines.  The vaccines utilized were a
modified live virus vaccine administered by the
intranasal route and an inactivated virus vaccine
injected intramuscularly.  Virus neutralization tests
were conducted on sera obtained at intervals before
and following vaccination.  Unfortunately, the calves
were apparently exposed naturally to PI-3 virus, and
the responses to that virus were inconclusive.
However, antibody responses to IBR virus were
dramatically enhanced by the combination of the two
vaccines.
Introduction
Immunization of young calves against respiratory
disease presents a major problem because the presence of
maternal antibodies may block the response to
vaccination.  Antibodies to infectious bovine
rhinotracheitis (IBR) and parainfluenza type 3 (PI-3)
viruses may persist in calves until several weeks of age
due to natural infection or vaccination of cows in the
herd.  Modified live virus vaccines administered by the
intranasal route have potential to induce immune
responses when some level of circulating maternal
antibodies are still present.  However, the level of
systemic antibodies produced to these vaccines is minimal
and the duration of immunity may be limited.  The
objective of this research was to determine if an intranasal
modified live virus vaccine utilized in combination with
an oil adjuvanted killed virus vaccine would enhance the
level of circulating (serum) antibodies in calves.
Materials and Methods
Seventy-one spring calves averaging about 90 days of
age were weaned and randomly assigned to one of four
treatment groups.  The number of animals in each group
and vaccination schedule are indicated in Table 1.  The
vaccines were a modified live IBR and PI-3 virus vaccine
(Nasalgen IP, Coopers Animal Health, Inc., Mundelein,
IL) administered intranasally and an inactivated virus
vaccine (Vira Shield 5, Grand Laboratories Inc.,
Larchwood, IA) administered intramuscularly.  The
reduced number of calves vaccinated at day 37 was due to the
death of a few calves and the reserving of 2 or 3 calves in each
group as controls to monitor for natural infection.  Modified
live virus vaccinates (Groups C and D) were in one corral
separated from controls or inactivated virus vaccinates
(Groups A and B) in another corral for the first 30 days of
experimentation.
Calves were bled for serum on days 0, 37 and 63.  The
serum was stored at –20oC until tested for antibodies to IBR
and PI-3 viruses by microtiter virus neutralization tests.
Table 1.  Groups of calves and vaccination schedule.
Day 0 Day 37
Group Vaccine Number* Vaccine Number
A None 18 VS 5** 12
B VS 5 18 VS 5 15
C N*** 17 VS 5 15
D N+VS 5 18 VS 5 15
*Number = Number of calves
**VS 5 = Vira Shield 5
***N = Nasalgen IP
Results and Discussion
A small number of calves, two or three in each group,
were not vaccinated on day 37 to monitor for natural
infections.  By that time calves in Group I (unvaccinated
controls) had enhanced titers to PI-3 virus indicating natural
exposure of the calves to this virus.  Therefore, data on PI-3
virus antibodies were inconclusive and are not presented.
There was no indication of IBR virus infection in the calves.
Mean IBR virus antibody titers for the various groups of
calves are provided in Figure 1.  At day 37 antibody titers in
Group A animals (unvaccinated controls) had declined, and
antibody responses of calves in Groups B and C were
minimal.  We anticipate that the response of Group C calves
(modified live virus) had peaked at this time although there
was potential for increasing titers in Group B calves
administered the oil adjuvanted killed virus vaccine.  Antibody
titers of the Group D calves were much higher than in calves
in the other groups.  This enhancement was pronounced at day
63 following a booster dose of killed virus vaccine as
indicated by the titers developed by calves in Groups C and D.
This experimentation demonstrated a priming effect by
the intranasal vaccine, which may have the potential to
immunize in the presence of some level of maternal
antibodies.  The priming effect is evident from the enhanced
response of Group C calves that received the inactivated virus
vaccine at day 37.  Administration of the two vaccines at the
same time followed by a booster of inactivated virus vaccine
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proved to be the best protocol.  The intranassal vaccine
has recognized ability to establish local or mucosal
immunity.  Also, the vaccine has been reported to induce
interferon production, which can provide early protection
against viral infection.  Use of these vaccines in
combination should be considered for immunization of
young calves.  Primary vaccination with the intranassal
vaccine provides early resistance to the viruses.
Secondary vaccination with inactivated virus vaccine
markedly enhances circulating antibody titers and probably
persisting resistance.
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Figure 1.  Mean  neutralizing IBR virus antibody titers in groups of calves vaccinated with several
protocols.  Group A: No vaccination on day 0, Vira Shield 5 on day 37.  Group B:  Vira Shield 5 on day
0 and day 37.  Group C:  Nasalgen on day 0 and Vira Shield 5 on day 37.  Group D:  Nasalgen plus Vira
Shield 5 on day 0 and Vira Shield 5 on day 37.
